The emergence and outbreak of the pandemic COVID-19, which according to the report of the World Health Organization (WHO) has killed more than 5 million worldwide people by the end of 2021, has shown that infectious diseases can be serious threats to the human generation. Infectious diseases have irreparable consequences on the social and economic affairs of countries and challenge the health care system [1, 2]. It is necessary to implement basic actions to minimize the problems. One of the performed actions is the research and development of substances that can eliminate pathogens. In this regard, various organic, inorganic, and organic-inorganic hybrids compounds have been introduced [3–5]. The use of silver has been common since ancient times, and today, silver-based compounds are still considered by researchers in the combat against various infectious agents due to their broad-spectrum antibacterial properties [6, 7]. Burn injuries are costly due to the relatively long treatment period, and unfortunately, lead to many deaths each year [8, 9]. Burn wounds can become infected as a result of contact with pathogens, which can delay the healing of the skin due to the formation of skin lesions and cause side effects [10, 11]. So far, various antibacterial agents have been studied to treat burn infections. One of the well-known silver compounds for healing infectious wound burns is silver sulfadiazine, which is used topically in the experimental and clinical treatment of second and third-degree vulnerable infection [12, 13], and delivered in the form of 1% commercial creams or aqueous suspension . In the silver sulfadiazine polymeric structure, there is a coordination bond between silver and sulfadiazine, and its antibacterial properties depend on the release of silver ions at the site of infection . In order to improve the antibacterial performance, enhancement of the solubility, prevented the aggregation, optimum drug availability, controlling release, reduction of posing problem and allergic reactions of silver ions in silver sulfadiazine [13, 15–19], efforts are being made to achieve systems that stabilize it on other materials. This strategy can provide opportunities to perform topical treatment with a targeted release of the loaded agent . In this regard, the loading of sulfadiazine silver on various materials such as: (ⅰ) biodegradable polymers or co-polymer supports (polyvinyl alcohol, polyrotaxane, zein, polyacrylonitrile, chitosan)[20–24], (ⅱ) inorganic meso/nano-porous material carriers (MCM-41, SBA-15 mesoporous silica particles) [16, 25, 26], (ⅲ) collagen and amino acid base material [13, 27, 28], (ⅳ) solid lipid , and (ⅴ) composite or a mixture of them [30–34] have been investigated in various efficient approaches such as wound dressing, film, creams, suspension, and gel formulations. MOFs are organic-inorganic hybrid compounds formed by the coordination of metal ions and organic ligands. Features such as high surface area, structural diversity, good physicochemical stability, biological degradation and compatibility, low toxicity, and the presence of cavities that can be hosts for various compounds make these compounds attractive materials in various applications [35, 36]. In recent years, the use of such structures for loading drugs and therapeutic compounds has been reported . Cu-BTC (also known as HKUST-1) is one of the famous MOFs that has been synthesized from copper ions and 1,3,5-Benzenetricarboxylic acid ligand. The presence of copper ions, which along with silver are among the well-known metals with antibacterial properties , having holes with a suitable volume of 9Å×9Å and good chemical-thermal stability, has introduced it not only as an antibacterial agent but also as a carrier for drug molecule [39–42]. In this report, we decided to test the potential of using Cu-BTC MOF as a carrier for silver sulfadiazine, considering the capacities expressed for them. After characterization of the structure, antibacterial activities were evaluated by agar well diffusion and plate colony count bioassays.